Doma Biopharmaceutical Funding: $134M Raised, Series A
Doma Biopharmaceutical has raised $134M in total funding. Latest round: Series A. Backed by Biocytogen, China Life Private Equity Investment, PICC Capital.
Doma Biopharmaceutical funding overview
Doma Biopharmaceutical has raised $134M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in June 2022. The round record for Doma Biopharmaceutical runs through 2022; nothing later has been disclosed. Investors on record include Biocytogen, China Life Private Equity Investment, PICC Capital, Suzhou Industrial Park Hefeng Capital, Taiping Healthcare Fund, CMB International and 1 others. 7 distinct backers are named across the disclosed rounds.
Doma Biopharmaceutical at a glance
Total raised
$134M
Latest round
Series A
Latest round date
June 2022
Notable investors
Biocytogen, China Life Private Equity Investment, PICC Capital, Suzhou Industrial Park Hefeng Capital, Taiping Healthcare Fund, CMB International, SDIC Venture Capital
Frequently asked about Doma Biopharmaceutical funding
How much has Doma Biopharmaceutical raised?
Doma Biopharmaceutical has raised $134M in total disclosed funding across the rounds on record.
Who has invested in Doma Biopharmaceutical?
Biocytogen, China Life Private Equity Investment, PICC Capital, Suzhou Industrial Park Hefeng Capital, Taiping Healthcare Fund, CMB International are named among the investors backing Doma Biopharmaceutical.
What was the latest Doma Biopharmaceutical funding round?
The most recent disclosed round is a Series A, announced in June 2022.
Where is Doma Biopharmaceutical based?
No headquarters location is disclosed for Doma Biopharmaceutical.
When did Doma Biopharmaceutical last raise?
The last disclosed Doma Biopharmaceutical round closed in June 2022 at Series A.
Doma Biopharmaceutical totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.
